USPTO issued a trademark registration for INREBIC (Registration No. TM86690908) covering pharmaceutical preparations for therapeutic use in beta thalassemia, myelodysplastic syndromes, blood diseases, cancer, and cytokine inhibitory drugs. The trademark was filed on July 13, 2015, and reached registered status on March 30, 2026.

Pharmaceutical companies and drug manufacturers should note this trademark registration when developing branding strategies for similar therapeutic products. The registration provides the trademark holder with federal protection in Class 5 (pharmaceuticals) and may be used to enforce against confusingly similar marks in the pharmaceutical space. No immediate compliance actions are required, but companies should ensure their product branding does not infringe on this registered mark.